Article: Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease—L.I. Backus, et. al. by Alan Franciscus
SOURCE: Hepatology doi: 10.1002/hep.29811
Study Aims and Results: The study was undertaken to understand the improved outcomes (defined as the lower risk of death) among treated patients compared to untreated patients. The treated patients received HCV direct-acting antiviral (DAA) medications.
The Veterans Affairs conducted the study. The patient population was comprised of 103,346 veterans with HCV genotypes 1, 2 and 3. Various HCV direct-acting antiviral (DAA) medications (interferon-free) were used to treat 40,664 Veterans. The overall cure rate in the treated group was 96.8%.
The groups (non-treated group vs. treated group) were compared for overall survival. The authors reported that there was a 69% reduction in all-cause deaths compared to the untreated patients.
Conclusions: DAA treatment and cure of hepatitis C in early stage HCV disease (without cirrhosis) dramatically decreased disease progression and death.
Editorial Comments: This study is the largest yet conducted with DAA HCV medications to show the benefit of being cured. In the analyses, the reduction in deaths is further proof of the effectiveness of DAA therapy.
The study confirms that DAA therapy reduces deaths and should settle the question of whether we should treat everyone with hepatitis C. That answer should be a resounding YES!
Alan Franciscus is the Executive Director of the Hepatitis C Support Project and the Editor-in-Chief of the HCV Advocate Website
Read the entire March HCV Advocate newsletter hereShare This Page